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Gregory L. Moneta, MD, Section EditorRevised Cardiac Risk Index (Lee) and Perioperative Cardiac Events as
Predictors of Long-Term Mortality in Patients Undergoing Endovas-
cular Abdominal Aortic Aneurysm Repair
Archan S, Roscher CR, Fairman RM, et al. J Cardiothorac Vasc Anesthesia
2010;24:84-90.
Conclusion: Long-term mortality is high after endovascular repair of
abdominal aortic aneurysm (AAA). In the setting of endovascular AAA
repair, the Lee Index may be useful for stratifying short-term and long-term
mortality in high-risk patients.
Summary: Perioperative myocardial infarction remains a vexing prob-
lem. In very high-risk vascular surgical patients, perioperative myocardial
ischemic injury may be as high as 18% to 35% (J Vasc Surg 2006;43:533-
538). Although a large majority of patients survive a perioperative myocar-
dial ischemic event, they are at risk of increased late mortality (J Vasc Surg
1994;20:598-604). Because it appears long-term survival is not improved by
endovascular aneurysm repair (EVAR) vs conventional open AAA repair, it is
reasonable to investigate whether patients undergoing EVAR can be strati-
fied according to the Revised Cardiac Risk Index (Lee). This was a retro-
spective review from a single academic medical center involving 225 patients
with AAA treated with EVAR between 1999 and 2006. The goal was to
determine if the Lee Index is useful is stratifying patients by risk of both
perioperative cardiacmorbidity and long-term all-causemortality. Data were
collected from physician quality assurance databases, office records, and
medical records. There were no in-hospital cardiac deaths. Themajor cardiac
adverse event (MACE) rate perioperatively was 6.2%. Long-term all-cause
mortality was 23%. By univariate analysis, a history of coronary artery disease
(likelihood ratio [LR], 8.7; P  .023), history of congestive heart failure
(LR, 4; P  .042), and a Revised Cardiac Risk Index (RCRI) 3 (LR, 8.6;
P  .004) were all predictors of perioperative MACE. Long-term all-cause
mortality was associated with a history of coronary artery disease (LR, 10.7;
P .002), perioperative cardiac events (LR, 15.9; P .0001), echocardio-
graphic evidence of myocardial infarction (LR, 8.5; P  .006), and exercise
tolerance of only on block (LR, 8.4; P  .005). Long-term mortality is
increased after perioperative cardiac events within the RCRI 3 subgroup
(LR, 6.1; P  .019).
Comment: It would seem logical that a patient who develops a
myocardial ischemic event after EVAR should undergo further evaluation
for coronary artery disease. Long-term survival appears significantly im-
paired after EVAR, and more so after even a minor myocardial infarction
following EVAR. Whether the minor perioperative myocardial event is a
cause of long-term mortality or merely a marker of long-term increased
cardiac risk is a question that deserves further investigation.
Eligibility for Statin Therapy by the JUPITER Trial Criteria and
Subsequent Mortality
Cushman M, McClure LA, Lakoski SG, et al. Am J Cardiol 2010;105:
77-81.
Conclusion: Applying JUPITER trial eligibility criteria, 21% of pa-
tients not eligible for lipid-lowering therapy by the guidelines proposed by
the National Cholesterol Education Program (NCEP) Adult Treatment
Panel (ATP) would be eligible for lipid-lowering therapy based on
JUPITER trial eligibility.
Summary: The JUPITER trial reported that individuals without dia-
betes who were not eligible for lipid-lowering therapy by traditional guide-
lines, but who had C-reactive protein levels (CRP) 2.0 mg/L, had a 20%
reduction in all cause mortality and a 44% reduction in vascular events with
rosuvastatin treatment compared with placebo. Patients were eligible for
JUPITER if they had a low-density lipoprotein cholesterol (LDL-C) level
130 mg/dL, no diabetes, no concurrent use of hormone replacement
therapy, a creatinine 2 mg/dL, and triglycerides 500 mg/dL. The
NCEP ATP (JAMA 2001;285:2486-97) has suggested strategies for pri-
mary prevention of coronary heart disease are appropriate in persons with
high levels of LDL-C (160 mg/dL) or those with borderline high LDL-C
(130-159 mg/dL) and multiple (2) risk factors. Therefore, patients eligi-
ble for JUPITER, inmany cases, would not be suggested for statin treatment
by the ATP III guidelines. The authors therefore sought to evaluate the
effect of applying JUPITER criteria vs those suggested by ATP III guidelines
to the general population. The study group consisted of 3229 participants in
the REasons for Geographic and Racial Differences in Stroke (REGARDS)
cohort. This is an observation study of white and African Americans aged
45 years. Fifty-six percent of the sample resides in the 10 southern “stroke
belt” states, with the rest from the other 38 contiguous states. Among
11,339 participants age-eligible for JUPITER and without a vascular diag-
518nosis or using lipid-lower therapy, 2342 (21%) met JUPITER criteria.
Compared with participants in the JUPITER study, they had similar LDL-C
and CRP levels, were more often women, black, and had metabolic syndrome.
At 3.5 years of follow-up, the mortality rate in REGARDS participants eligible
for JUPITER was 1.17 per 100 patient-years (95% CI, 0.94-1.42). Compared
with those who were otherwise eligible for JUPITER who had CRP levels2
mg/L (n  2620), those with CRP levels 2 mg/L had an adjusted relative
total mortality risk of 1.5 (95% CI, 1.1-2.2).
Comment: The implication of the article is that CRP testing should be
added to risk stratification of vascular disease and that many thousands of
patients potentially benefiting from statin therapy are not being offered
treatment. Almost half of REGARDS participants eligible for JUPITER on
the basis of clinical factors before CRP testing were eligible on the basis of
having CRP levels2mg/L. REGARDS participants eligible for JUPITER,
who did not meet ATP III guidelines for lipid lowering but who had a CRP
level2 mg/L, had a 50% greater mortality than those with CRP levels2
mg/L. The bottom line is that if JUPITER criteria are applied for applica-
tion of lipid-lowering therapy, twice as many individuals would be eligible
for lipid-lowering therapy compared with those eligible by ATP III guide-
lines.
Long-Term Outcome of Open or Endovascular Repair of Abdominal
Aortic Aneurysm
De Bruin JL, Baas AF, Buth J, and the DREAMStudy Group. N Engl JMed
2010;362:1881-9.
Conclusions: Long-term survival after open and endovascular abdom-
inal aortic aneurysm (AAA) repair is the same, but endovascular repair is
more expensive and is associated with more reinterventions.
Summary: These are 6-year outcome data of the DREAM trial, a
long-term multicenter, randomized, controlled trial comparing open repair
with endovascular repair in 351 patients with AAAs 5 cm in diameter.
Patients were considered suitable candidates for either open or endovascular
repair. The primary outcomes were rates of death from any cause and
reintervention. This article appeared in the same issue of the New England
Journal of Medicine as the long-term results of EVAR 1 and EVAR 2 and
provides additional long-term follow-up of the effectiveness and durability
of endovascular AAA repair. (The 2-year data were published in 2005 by
Blankensteijn JD, et al, N Engl J Med 2005;352:2398-405). A total of 173
patients were randomized to undergo endovascular repair, and 178 were
assigned to open repair. Kaplan-Meier methods were used to calculate
survival on an intention-to-treat basis. At 6 years after randomization,
cumulative survival rates for open and endovascular repair were 69.9% and
68.9%, respectively (difference, 1.0 percentage point; 95% CI, 1.8 to 10.8;
P  .97). Cumulative rates of freedom from secondary intervention were
81.9% for open repair and 70.4% for endovascular repair (difference, 11.5
percentage points; 95% CI, 2.0-21.0; P  .03).
Comment: The results of this study mirror very closely the long-term
results of EVAR 1 (N Engl J Med 2010;362:1863-71). Like EVAR 1,
DREAM concluded there is no long-term survival advantage of endovascu-
lar repair vs open repair for AAA, and endovascular repair is more expensive
and requires more reinterventions. However, despite lack of long-term
efficacy of endovascular repair compared with open repair, physicians and
patients both like endovascular repair. In effect, this genie is already out of
the bottle. These data and data from EVAR 1 should provide material for
surgeons to have open and objective discussions with their patients about
alternatives for treatment of AAA. It remains to be seen whether payers will
begin to demand justification for endovascular repair over an open proce-
dure. Logically, it seems they could and perhaps should.
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration. JAMA 2009;302:1993-2000.
Conclusion: It is possible to simplify lipid assessment in vascular
disease by measuring either total high-density lipoprotein (HDL) choles-
terol (HDL-C) levels or apolipoproteins. It is not necessary to fast or
measure triglyceride levels.
Summary: There is a disagreement among lipid experts about whether
assessment of apolipoprotein A1 (apo A1), and apolipoprotein B (apo B),
should replace assessment of HDL-C and total cholesterol levels for assess-
ment of vascular risk. Although there is agreement on the value of reducing
low-density lipoprotein cholesterol (LDL-C) it is unclear whether there is
benefit in modification or measurement of triglycerides or HDL-C (JAMA
2001;285:2486-97). In addition, failure of torcetrapib has led to questions
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characterize the relationship between HDL-C and vascular risk, especially at
the high HDL-C levels (N Engl J Med 2007;357:2109-22). Given uncer-
tainties of the relationship between LDL-C and HDL-C levels and the
various manifestations of vascular disease, as well as the uncertainties of the
roll of proatherogenic lipoproteins in various types of vascular disease, the
authors sought to produce reliable estimates of the association of major
lipids and apolipoproteins with respect to risk for ischemic stroke and
coronary heart disease (CHD). A total of 112 prospective studies of cardio-
vascular risk factors involving 1.2 million participants with shared individual
medical records are in the Emerging Risk Factors Collaboration (ERFC).
Sixty-eight studies involving 302,430 participants without any known his-
tory of CHD at initial examination also had complete information on
baseline levels of total cholesterol, HDL-C, and triglyceride, and several
conventional risk factors for vascular disease (diabetes, blood pressure, body
mass index, smoking status, age, and sex). These patients had a total of 2.79
million person-years of follow-up. During follow-up, there were 8857
nonfatal myocardial infarctions, 2534 ischemic strokes, 3928 coronary heart
disease deaths, 513 hemorrhagic strokes, and 2536 unclassified strokes. The
lipid information and the outcome information was used to calculate hazard
ratios adjusted for conventional variables. Rates of CHD per 1000 person-
years in the bottom and top thirds of baseline lipid distributions, respec-
tively, were 2.6 and 2.2 for triglycerides, 6.4 and 2.4 for HDL-C, and 2.3
and 6.7 for non-HDL-C. The adjusted hazard ratio for CHDwas 0.99 (95%
CI 0.94-1.04) for triglycerides, 0.78 (95% CI 0.74-0.82) for HDL-C, and
1.5 (95% CI, 1.39-1.61) for non-HDL-C. Hazard ratios were as strong in
participants who did not fast as those did. A combination of 80 mg/dL
lower non-HDL-C and 15 mg/dL high HDL-C resulted in a hazard ratio
for CHDof 0.35 (95% CI, 0.3-0.42). For the subset with apolipoproteins or
directly measured LDL-C, hazard ratios were 1.5 (95% CI, 1.38-1.62), with
a ratio of non-HDL-C/HDL-C the hazard ratio was 1.49 (95% CI, 1.39-
1.60), with a ratio of apo B/apo A1, the hazard ratio was 1.42 (95% CI,
1.06-1.91), and with a non-HDL-C the hazard ratio was 1.38 (95% CI,
1.09-1.73). With directly measured LDL-C, hazard ratios for ischemic
stroke were 1.02 (95% CI, 0.94-1.11) with triglycerides, 0.93 (95% CI,
0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C.
Comment: The data are important but complicated as presented. Never-
theless, the implications of the findings can be simplified as follows: What to
measure in vascular risk assessment depends more on practical considerations
rather than major differences in strength of epidemiologic associations. In
addition, hazard ratios for vascular disease with lipid levels are of similar
magnitude in fasted and non-fasted patients. Hazard ratios are also similar with
directlymeasuredLDL-Candnon-HDL-C. Finally, triglyceride concentrations
are not independently related to coronary heart disease risk. The bottom line is
that lipid assessment for stratifying vascular risk can done by measuring either
total cholesterol andHDL-C levels or apolipoproteins, without the need to fast
and without the need to monitor triglycerides.
National Outcomes after Open Repair of Abdominal Aortic Aneurysms
with Visceral or Renal Bypass
Martin MC, Giles KA, Pomposelli FB, et al. Ann Vasc Surg 2010;24:
106-12.
Conclusion: Mortality of open abdominal aortic aneurysm (AAA)
repair that includes visceral or renal artery bypass is higher than for open
AAA repair without visceral or renal artery bypass and depends on increasing
age and the presence of renal or congestive heart failure.
Summary:There is extensive literature evaluating the outcome of open
infrarenal AAA repairs. However, when AAA repair includes a visceral or
renal artery bypass, data are much more limited (Ann Surg 1996;223:555-
67; Langenbecks Arch Surg 2007;392:725-30). In this study, the authors
sought to evaluate national outcomes of open elective AAA repair with and
without a mesenteric or renal artery bypass and predictors of risk and
perioperative mortality.
The National Inpatient Sample database from 1993 to 2006 was used.
ICD-9 codes for open repair of intact AAA were used to identify open AAA
repairs with and without visceral or renal artery bypass (VRB). VRBs were
defined as aortorenal and/or mesenteric bypass or a mesenteric endarterec-
tomy. Patients with aortic dissections were excluded. Complications and
mortality of patients with standard open repairs of infrarenal AAAs were
compared with those patients who also had visceral or renal artery bypass.
Multivariate logistic regression analysis was then used to analyze predictors
of perioperative mortality.
The study identified 31,166 VRB and 362, 808 infrarenal AAA repairs.
Over the time period, VRB repair volume decreased by 58% and open
infrarenal AAA repair volume decreased by 59%. Mortality was higher in the
VRB patients (5.8 vs 4.4%, P .01). There were more complications in the
VRB patients: acute renal failure, 9.5% vs 6.0% (P  .01), acute mesenteric
ischemia, 2.0% vs 1.2%; and bowel resection, 1.1% vs 0.8% (P  .01).
Mortality was 10 times more likely if the patient required a bowel resection
or developed acute renal failure. Independent preoperative predictors of
mortality were VRB (odds ratio [OR], 1.3; 95% CI, 1.2-1.5), age (OR, 1.4
per decade; 95% CI, 1.4-1.5), chronic renal failure (OR, 5.5; 95% CI,4.9-6.3), congestive heart failure (OR, 7.5; 95% CI, 6.1-9.3), and pulmo-
nary disease (OR, 1.2; 95% CI, 1.1-1.2).
Comment: This study has all the advantages and disadvantages of a
myriad of similar studies that are appearing in the vascular surgical literature.
Such studies are limited in their ability to distinguish primary diagnoses and
procedures and accurately identify comorbid conditions and complications.
The database used here, the National Inpatient Sample, does not actually
analyze all patients. They use sampling weightings to derive total population
estimates. Nevertheless, the conclusion that open AAA repair combined
with visceral or renal artery bypass has higher mortality and complication
rates than standard infrarenal open AAA repair makes sense. This combined
with the recently published ASTRAL trial (N Engl J Med 2009;361:1953-
62) should make surgeons reconsider performance of renal revascularization
as part of AAA repair if the renal revascularization is not integral to the repair.
Randomized Placebo-Controlled Crossover Trial of Tadalafil in
Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Schiopu E, Hsu VM, Impens AJ, et al. J Rheumatol 2009;36:2264-8.
Conclusion: Tadalafil is well tolerated and safe in patients with sys-
temic sclerosis but lacks efficacy in comparison with placebo.
Summary: The endothelial injury of systemic sclerosis is associated
with decreased nitric oxide production (Kahaleh et al, Rheum Diseases Clin
N Am 2008;34:57-71). Type V cyclic GMP phosphodiesterase (PDE-5)
affects the tone of smooth muscle. An intracellular regulator of smooth
muscle tone is cyclic nucleotide monophosphate, cGMP. Nitric oxide syn-
thase produces nitric oxide. Through a complex pathway, nitric oxide
facilitates conversion of GTP into cGMP. PDE-5 breaks down intracellular
cGMP. Therefore, inhibition of PDE-5 results in increased availability of
intracellular cGMP and results in vasodilatation. Tadalafil is a PDE-5 inhib-
itor effective in the use of male erectile dysfunction. However, PDE-5
inhibitors have also been suggested as beneficial in patients with severe
Raynaud’s syndrome (Fries R et al, Circulation 2005;119:2980-5). Tadalafil
is an intriguing PDE-5 inhibitor in that it has a half-life of 17.5 hours and
efficacy up to 36 hours. The pharmacokinetics of tadalafil are not affected by
food or alcohol, age, diabetes, or moderate hepatic insufficiency. It therefore
would seem an ideal drug for facilitating vasodilatation in patients with
Raynaud’s syndrome. This was a randomized, prospective, double-blind,
placebo-controlled, crossover study comparing oral tadalafil with a fixed
daily dose of 20 mg for 4 weeks vs placebo. The study was conducted in
patients with Raynaud’s syndrome secondary to systemic sclerosis. Thirty-
nine completed the study. All patients fulfilled American College of Rheu-
matology classification criteria for systemic sclerosis. All were at least 18 years
of age and had evidence of at least six Raynaud’s attacks during the 2-week
pretreatment period. Patients with unstable angina, congestive heart failure,
or use of nitrites for angina pectoris or any other condition as well as those
with significant central nervous system disease were excluded. Before enroll-
ment, all patients discontinued any other type of vasodilator. Patients were
evaluated for duration and frequency of Raynaud’s attacks and Raynaud
condition scores (RCS). At the end of the evaluation period, there were no
significant statistical differences in RCS scores, frequency of Raynaud’s
attacks, or duration of Raynaud’s attacks between the treatment and placebo
groups.
Comment: The results of the study are disappointing but not conclu-
sive. The participants in this trial had a longer duration of Raynaud’s
syndrome than those in other trials. Severity of Raynaud’s syndrome second-
ary to systemic sclerosis often increases over time. Patients heremay have had
greater endothelial cumulative damage than those in other studies. Other
studies have primarily evaluated the effect of PDE-5 inhibitors on ulcer
healing. Only two patients in this study had active digital ulcers. However,
overall, the current results do not support the use of tadalafil as treatment for
Raynaud’s syndrome secondary to systemic sclerosis at the dosage of 20
mg/d. The study was also burdened by a large placebo effect.
Renal Artery Revascularization Improves Heart Failure Control in
Patients with Atherosclerotic Renal Artery Stenosis
Kane GC, Xu N, Mistrik E, Roubicek T, et al. Nephrol Dial Transplant
2010;25:813-20.
Conclusion: Patients with atherosclerotic renal artery stenosis (RAS)
presenting for percutaneous transluminal renal angioplasty have an increased
risk of death after renal angioplasty. Renal artery revascularization results in
improvement in heart failure control and a reduction in heart failure-related
hospitalizations.
Summary: RAS is associated with abnormalities of left ventricular
function and structure as well as episodes of flash pulmonary edema (acute
left ventricular failure). These are thought to be mediated through labile
systemic hypertension with exacerbation of myocardial ischemia (J Am Soc
Nephrol 2005;16:2746-53; N Engl J Med 2001;344:17-22). Progressive
RAS can be a major determinant of outcome in patients with heart failure
(J Am Coll Cardiol 2006;47:1987-96). Frequently accepted indications for
renal artery revascularization include episodes of flash pulmonary edema,
